Merck says osteoporosis drug achieves goal in large trial
September 15, 2014 at 13:56 PM EDT
Sept 15 (Reuters) - Merck & Co on Monday said it expects next year to seek U.S. approval for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary effectiveness goals in a late-stage trial.
